Marcelo A. S. Toledo

This study shows that nanoparticle size affects their uptake by myeloid cells and delivery to hematopoietic organs in myeloproliferative neoplasms.

This study shows that melatonin nanoparticles reduce myeloproliferative neoplasm symptoms by targeting metabolic, inflammatory, and fibrotic pathways.

This paper identifies PDE3A-SLFN12 molecular glues as a novel therapeutic target for KIT D816V-driven mast cell malignancies, showing their efficacy in killing multiple KIT D816V cell types and synergy with tyrosine kinase inhibitors.

This study identifies a novel mechanism in myelofibrosis where a single mutation drives both bone formation and resorption, revealing THBS1 as a therapeutic target.

This study shows that the JAK2 V617F mutation enhances IL-6 sensitivity by promoting gp130 dimerization and expression in myeloid cells, contributing to chronic inflammation in MPN.

This study identifies JAK2V617F zygosity-specific vascular changes in MPN and shows IFNα inhibits EndMT, offering a novel antifibrotic mechanism.